AbbVie Says Humira's Many Patents Is No Antitrust Violation
AbbVie and several other drugmakers have asked an Illinois federal court to dismiss a sweeping proposed class action accusing the company of illegally shielding its immunosuppressant Humira from competition with a "patent...To view the full article, register now.
Already a subscriber? Click here to view full article